EDIT

Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotechnology company founded in 2013 and based in Cambridge, Massachusetts. The company was originally incorporated as Gengine, Inc. before changing its name in November 2013. Editas went public in February 2016 and has since established itself as a pioneer in the genome editing field, focusing on developing transformative genomic medicines using CRISPR technology to treat serious diseases. The company operates primarily in the gene therapy and cell therapy sectors, with programs targeting inherited diseases, blood disorders, and cancer.